Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.

In pharmaceutical development, where most therapies never reach the market, early and strategic data investments can make all the difference.

This study was run to understand variations in treatment with resulting shifts in care management that aligns with patient preferences and migraine-specific care and observe if a relationship exists between racially diverse patients seeking care and healthcare provider (HCP) specialties, including alternative medicine providers. Diane Faraone, PharmD, Karina D’Angelo PhD., Andreas Lysandropoulos, MD, PhD. Background…

Clinical trials are just the start. Discover how real-world data help life sciences companies implement market access strategies designed to get new drugs to patients who need them.

In today’s outcomes-driven healthcare landscape, real-world data (RWD) and real-world evidence (RWE) have emerged as critical tools to demonstrate clinical value, return on investment (ROI) and long-term impact beyond controlled trial environments.

Generic drugs don’t usually grab headlines. They’re dependable, low-cost and mostly stay in the background. But behind that generic label is a global system that’s far more fragile, and far more important, than it seems. Today, that system is under serious pressure. The United States is facing everything from supply chain disruptions and political instability…

This research, led by Grace K. Kane, Douglas Londono, and Nathan J. Markward, explores how the timing of biomarker testing affects survival outcomes in patients with non-small cell lung cancer (NSCLC). Using real-world claims data, it identifies disparities in testing and treatment patterns and their impact on mortality rates. Biomarker testing is essential to advancing…

Headache disorders including migraine are highly prevalent globally, estimated to affect more than 50% of the population at any point and time. In the U.S., migraine patients spend an average of $9,000 more than those without the diagnosis.

Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey.